Lit Matters: PE Guideline Update

Acute pulmonary embolism is no longer framed as simply massive, submassive, or low risk. The 2026 AHA/ACC guideline replaces that scheme with a category-based PE severity model, links treatment to shock physiology and RV strain, and makes outpatient DOAC-based care the default for selected low-risk patients.

New PE Severity Framework

• Category-based risk language: The old massive and submassive labels are gone, replaced by Categories A through E to better separate incidental PE, intermediate-risk disease, and overt hemodynamic failure.
• Intermediate-risk gray zone: Category C captures the normotensive patient with symptomatic PE, then separates C1, C2, and C3 by RV strain and biomarker burden rather than a single submassive bucket.
• Respiratory compromise modifier: An R-plus modifier flags hypoxia or tachypnea as a meaningful layer of severity even when blood pressure is preserved, a distinction worth hearing in the chapter.
• Shock without hypotension: Category D explicitly includes transient hypotension and normotensive shock with end-organ hypoperfusion, recognizing that preserved BP does not exclude impending collapse.
• Arrest-level PE severity: Category E separates overt shock from cardiac arrest, clarifying when PE has progressed from unstable physiology to a true crashing presentation.

Management Changes in Acute PE

• Outpatient low-risk treatment: Categories A and B can often leave the hospital on anticoagulation if follow-up and medication access are in place, rather than defaulting to automatic admission.
• Limited role for procedures: For C1 PE, intervention has no recommended role, while catheter-based therapy or thrombectomy in C2 and C3 remains only a cautious may-consider option.
• Equivalent reperfusion options: In Category E1, systemic thrombolysis and catheter-based therapy now sit on similar footing instead of one clearly outranking the other. We get into the bedside implications in the episode.
• Immediate lytics in arrest: For Category E2 PE with crashing physiology or cardiac arrest, the headline move is push systemic thrombolytics without waiting for a longer deliberation.
• Anticoagulation simplification: LMWH is favored over unfractionated heparin, and apixaban or rivaroxaban are first-line outpatient agents, marking a shift away from routine heparin drips and warfarin.
• PERT and follow-up structure: Pulmonary Embolism Response Teams get strong guideline support, paired with an early check-in around one week and formal reassessment at three months.